Treatment with Iscador, Patients with Primary Non-Metastatic Colorectal Carcinoma
  

<< back

By: Friedel MD, Matthes MD, Heusser MD, MME, Bock MD

Treatment with Fermented Mistletoe (Viscum Album L.) Extract as Part of Long-Term Supportive Care in Patients with Primary Non-Metastatic Colorectal CArcinoma

W.E. Friedel MD, H. Matthes MD, P. Heusser MD, MME, P.R. Bock MD

A multicenter, epidemiological, observational cohort study on 804 (429 Iscador and 375 control) evaluable patients from 26 centers in Germany and Switzerland showed that the Iscador treatment was well tolerated and was beneficial in the long-term supportive care of patients with primary non-metastatic colorectal carcinoma.

Colorectal_SIO 2007.red.pdf 

Note: this poster was presented at the 2007 SIO Conference in S.F. by Dr. Peter Heusser, former Head of the Lukas Klinik, Arlesheim, Switzerland.


Please address your questions or comments to:

Michele Sanz
Medical Division Manager
Weleda North
America

1 Closter Rd
Palisades, NY 10964
Phone: 1.800.241.1030, ext. 5550
Direct: 1.845.510.5550
Cell: 1.845.480.2260
Fax: 1.845.365.8260 /
michele@weleda.com





<< back

Dynamic Content Management by ContentTrakker